Literature DB >> 12788877

Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.

T Vilsbøll1, T Krarup, J Sonne, S Madsbad, A Vølund, A G Juul, J J Holst.   

Abstract

Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are incretin hormones secreted in response to meal ingestion, thereby enhancing postprandial insulin secretion. Therefore, an attenuated incretin response could contribute to the impaired insulin responses in patients with diabetes mellitus. The aim of the present investigation was to investigate incretin secretion, in obesity and type 1 and type 2 diabetes mellitus, and its dependence on the magnitude of the meal stimulus. Plasma concentrations of incretin hormones (total, reflecting secretion and intact, reflecting potential action) were measured during two meal tests (260 kcal and 520 kcal) in eight type 1 diabetic patients, eight lean healthy subjects, eight obese type 2 diabetic patients, and eight obese healthy subjects. Both in diabetic patients and in healthy subjects, significant increases in GLP-1 and GIP concentrations were seen after ingestion of both meals. The incretin responses were significantly higher in all groups after the large meal, compared with the small meal, with correspondingly higher C-peptide responses. Both type 1 and type 2 diabetic patients had normal GIP responses, compared with healthy subjects, whereas decreased GLP-1 responses were seen in type 2 diabetic patients, compared with matched obese healthy subjects. Incremental GLP-1 responses were normal in type 1 diabetic patients. Increased fasting concentrations of GIP and an early enhanced postprandial GIP response were seen in obese, compared with lean healthy subjects, whereas GLP-1 responses were the same in the two groups. beta-cell sensitivity to glucose, evaluated as the slope of insulin secretion rates vs. plasma glucose concentration, tended to increase in both type 2 diabetic patients (29%, P = 0.19) and obese healthy subjects (22% P = 0.04) during the large meal, compared with the small meal, perhaps reflecting the increased incretin response. We conclude: 1) that a decreased GLP-1 secretion may contribute to impaired insulin secretion in type 2 diabetes mellitus, whereas GIP and GLP-1 secretion is normal in type 1 diabetic patients; and 2) that it is possible to modulate the beta-cell sensitivity to glucose in obese healthy subjects, and possibly also in type 2 diabetic patients, by giving them a large meal, compared with a small meal.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12788877     DOI: 10.1210/jc.2002-021873

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  152 in total

Review 1.  Impact of postprandial glycaemia on health and prevention of disease.

Authors:  E E Blaak; J-M Antoine; D Benton; I Björck; L Bozzetto; F Brouns; M Diamant; L Dye; T Hulshof; J J Holst; D J Lamport; M Laville; C L Lawton; A Meheust; A Nilson; S Normand; A A Rivellese; S Theis; S S Torekov; S Vinoy
Journal:  Obes Rev       Date:  2012-07-11       Impact factor: 9.213

Review 2.  Glucagon-like peptide 1 (GLP-1).

Authors:  T D Müller; B Finan; S R Bloom; D D'Alessio; D J Drucker; P R Flatt; A Fritsche; F Gribble; H J Grill; J F Habener; J J Holst; W Langhans; J J Meier; M A Nauck; D Perez-Tilve; A Pocai; F Reimann; D A Sandoval; T W Schwartz; R J Seeley; K Stemmer; M Tang-Christensen; S C Woods; R D DiMarchi; M H Tschöp
Journal:  Mol Metab       Date:  2019-09-30       Impact factor: 7.422

3.  The effect of duodenal-jejunal bypass on glucose-dependent insulinotropic polypeptide secretion in Wistar rats.

Authors:  Tammy L Kindel; Stephanie M Yoder; David A D'Alessio; Patrick Tso
Journal:  Obes Surg       Date:  2010-02-23       Impact factor: 4.129

4.  GLP-1 released to the mesenteric lymph duct in mice: effects of glucose and fat.

Authors:  Lena Ohlsson; Alison B Kohan; Patrick Tso; Bo Ahrén
Journal:  Regul Pept       Date:  2014-02-28

Review 5.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

6.  GLP-1R activation for the treatment of stroke: updating and future perspectives.

Authors:  Vladimer Darsalia; David Nathanson; Thomas Nyström; Thomas Klein; Åke Sjöholm; Cesare Patrone
Journal:  Rev Endocr Metab Disord       Date:  2014-09       Impact factor: 6.514

7.  GLP-1 at physiological concentrations recruits skeletal and cardiac muscle microvasculature in healthy humans.

Authors:  Sharmila C Subaran; Matthew A Sauder; Weidong Chai; Linda A Jahn; Dale E Fowler; Kevin W Aylor; Ananda Basu; Zhenqi Liu
Journal:  Clin Sci (Lond)       Date:  2014-08       Impact factor: 6.124

8.  Insulin regulates glucagon-like peptide-1 secretion from the enteroendocrine L cell.

Authors:  Gareth E Lim; Guan J Huang; Nina Flora; Derek LeRoith; Christopher J Rhodes; Patricia L Brubaker
Journal:  Endocrinology       Date:  2008-09-25       Impact factor: 4.736

9.  Effects of short-term intensive glycemic control on insulin, glucagon, and glucagon-like peptide-1 secretion in patients with Type 2 diabetes.

Authors:  M Shimodaira; Y Muroya; N Kumagai; K Tsuzawa; K Honda
Journal:  J Endocrinol Invest       Date:  2013-04-12       Impact factor: 4.256

10.  Dipeptidyl peptidase 4 (DPP-4) is expressed in mouse and human islets and its activity is decreased in human islets from individuals with type 2 diabetes.

Authors:  Bilal A Omar; Liu Liehua; Yuchiro Yamada; Yutaka Seino; Piero Marchetti; B Ahrén
Journal:  Diabetologia       Date:  2014-06-18       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.